Poor
Needs Revision
Patient Risk:
High
Summary
Several claims that would affect dosing/administration, patient selection, and follow-up are marked as not supported by the provided FDA label excerpts (e.g., once-daily timing, starting dose, dose adjustment/monitoring timeframe, pediatric use recommendation, elderly dose reduction). Only a subset of claims (indications, hypersensitivity contraindication, and increased bleeding risk with antithrombotics) are supported.
Category Scores
Accurate Statements
Vascepa is used as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Label 1 INDICATIONS AND USAGE
Vascepa is used as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus with 2 or more additional risk factors for cardiovascular disease.
Label 1 INDICATIONS AND USAGE
Vascepa is contraindicated in patients with known hypersensitivity to VASCEPA or any of its components.
Label 4 CONTRAINDICATIONS
Vascepa is associated with an increased risk of bleeding, and bleeding incidence is greater with concomitant antithrombotic medications such as aspirin, clopidogrel, or warfarin.
Label 5.3 Bleeding
Patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents should be monitored for bleeding.
Label 7.1 Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents
Vascepa capsules include 1 gram (1 gram amber-colored, oblong, soft-gelatin capsules).
Label 3 DOSAGE FORMS AND STRENGTHS
Unsupported Statements
Vascepa is a prescription-only medication.
Not supported by the provided label excerpts.
Vascepa is typically taken once daily with a meal.
No support in provided label excerpts for this specific dosing frequency/timing.
Vascepa is typically prescribed for patients with coronary heart disease or peripheral artery disease.
Not supported by provided label excerpts.
Vascepa is typically prescribed for statin-treated patients with high triglycerides (≥ 200 mg/dL) and elevated apolipoprotein B (ApoB).
Not supported by provided label excerpts.
The recommended starting dose of Vascepa is 2,000 mg (2 capsules) once daily with a meal.
Not supported by provided label excerpts.
The dose may be adjusted based on the patient's response to treatment.
Not supported by provided label excerpts.
Treatment response is typically evaluated after 4-8 weeks.
Not supported by provided label excerpts.
Taking more than the recommended dose is not recommended.
Not supported by provided label excerpts.
Taking more than the recommended dose may increase the risk of adverse effects.
Not supported by provided label excerpts.
Use of Vascepa in pediatric patients is not recommended.
Provided label excerpt states safety/effectiveness have not been established, but does not support a specific 'not recommended' directive.
In elderly patients, the starting dose may be reduced to 1,000 mg (1 capsule) once daily to minimize the risk of adverse effects.
Provided geriatric excerpt discusses no overall differences; it does not provide a dose-reduction recommendation.
Vascepa is contraindicated in patients with concomitant use of other omega-3 fatty acid medications.
Not supported by provided label excerpts.
Common adverse effects of Vascepa include abdominal pain, nausea, vomiting, diarrhea, and constipation.
No adverse reaction list of 'common adverse effects' is provided in the provided label excerpts.
Vascepa is protected by a patent that expires in 2025; after expiry generic versions may become available; generic availability could increase competition and lower prices.
Not supported by provided label excerpts.
Vascepa should be taken with a meal to minimize the risk of adverse effects.
Not supported by provided label excerpts.
The effects of Vascepa may be seen within 4-8 weeks of treatment.
Not supported by provided label excerpts.
Contradictions
Low
AI Statement
Vascepa is contraindicated in patients with concomitant use of other omega-3 fatty acid medications.
Label Reference
Label 4 CONTRAINDICATIONS (only hypersensitivity contraindication is shown in the provided excerpts)
Low
AI Statement
Use of Vascepa in pediatric patients is not recommended.
Label Reference
Label 8.4 Pediatric Use (Safety and effectiveness have not been established)
Important Omissions
Key dosing-and-administration details (e.g., exact recommended dosing regimen(s), how to take including any swallow instructions, and duration/follow-up statements) are not validated against the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple claims include specific dosing/administration and monitoring guidance that are not supported by the provided label excerpts, which could lead to deviation from FDA-labeled use. Additional unsupported pediatric and elderly dosing assertions increase the likelihood of non-label practice.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Many actionable administration/dosing and patient-selection claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to the provided label-supported content (indications, hypersensitivity contraindication, bleeding risk/monitoring with antithrombotics, and the stated pediatric 'not established' language). Remove or re-verify unsupported dosing, timing, dose-adjustment, elderly dose-reduction, generic/patent, and specific 'common adverse effects' statements against the full label sections not included in the excerpts.